Astaxanthin has demonstrated an excellent safety profile in numerous clinical studies, with no significant adverse effects reported even with long-term use
379,380,381 Researches on integrity and function of BBB at molecular level after non-invasive regulation should also be performed to verify the biosafety
All data and statistical summaries were presented in aggregated form, and no identifiable personal information was accessible
Studies have shown that the MLH1 protein, critical for regulating the MMR pathway, when under-expressed owing to hypermethylation of the hMLH1 gene promoter, resulted in decreased sensitivity in cancer cells
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
The fix: Strategic calorie distribution rather than restriction alone